GenoMed's Dr. David Moskowitz to Speak at FACES 2004, An Encephalitis Support Group
FOR IMMEDIATE RELEASE
Contact: Dr. David Moskowitz GenoMed, Inc. tel. 314-983-9933
August 4, 2004--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation DM(tm) (Disease Management) company, announced today that its Chairman and CEO, Dr. David Moskowitz, will be speaking at the Third Annual FACES Conference to be held Aug 6-8, 2004 in Enfield, CT (www.encephalitisglobal.com).
FACES stands for Friends and Caregivers, Encephalitis Survivors.
Dr. Moskowitz's topic Aug 6th will be "A Novel Approach to Encephalitis."
GenoMed has published its first case series of patients treated for acute encephalitis due to West Nile virus. The same treatment appears to be useful for patients who experienced acute encephalitis months or even years earlier, and still have headache, fatigue, or even paralysis. An example is Mr. Thomas Cook, who was recently filmed by WCVB TV 5 (Boston):
thebostonchannel.com
GenoMed's approach, since it targets an overly exuberant host immune response, should work for any virus in any immunocompetent patient. Dr. Moskowitz will be offering this treatment for free to encephalitis patients at the conference.
About GenoMed
GenoMed uses knowledge of disease-causing genes to improve patient outcomes. The Company has perfected the art of the free clinical trial. This summer GenoMed is conducting a free national trial for West Nile virus using already existing, FDA-approved drugs. To enroll, click on the "West Nile trial" link at genomedics.com. |
